Novo Nordisk, Eli Lilly and obesity
Digest more
2hon MSN
Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report
Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...
The overhaul comes after the foundation ousted former chief executive Lars Fruergaard Jørgensen in May, blaming him for an ...
Novo Nordisk's board changes stem from disagreements with the Novo Nordisk Foundation over board composition and strategic ...
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle room when companies pay to sponsor online search results.
(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up ...
Novo Nordisk will hold an Extraordinary General Meeting to elect new board members due to a disagreement with the Foundation over board composition. Key board members, including Chair Helge Lund, will ...
Novo Nordisk has topped Pfizer’s offer for Metsera with a bid of up to US$9 billion, seeking to secure Metsera’s obesity-drug ...
Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter, but management reduced 2025 guidance to 8%-14% sales growth and 10%-16% ...
Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo Nordisk A/S is called to elect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback